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Abstract
Background: Sutherlandia frutescens (L) R.Br. is one of traditional herbal medicines that formed the basis of primary
health care systems since the earliest days and is still widely used. Sutherlandia is prescribed for people with
tuberculosis (TB), but is still not known which compound(s) acts against M. tuberculosis and its mode of action.
The aim of this study was to identify and isolate antimycobacterial compounds from S. frutescens extracts against
shikimate kinase, a drug target for M. tuberculosis.
Methods: S. frutescens were dried, ground and extracted with ethanol, dichloromethane: methanol and water.
Fractionation and separation of compounds was done with column chromatography. Chromatograms were
developed in butanol/acetic acid/water (BAW) [21:6:3]; chloroform/methanol/water/formic acid (CMWF1) [60:15:2:1]
and (CMWF2) [21:9:1:0.3]. Separation and isolation of active compounds were done using preparative HPLC. The
activity of the plant extracts were also screened against shikimate kinase enzyme (MtbSK) using the MtbSK
inhibition assay.
Results: The DCM: MeOH (1:1) extract showed a high percentage inhibition (with an IC50 of 0.1 μg/ml) of MtbSK
and the purified inhibitor was an Alpha-Linolenic Acid (ALA) compound and it had a significant IC50 of 3.7 μg/ml.
Conclusions: This study demonstrated that ALA from S. frustescens is an inhibitor of shikimate kinase a good drug
target for M. tuberculosis.
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Background
Sutherlandia frutescens (L) R.Br. is one of traditional
herbal medicines that formed the basis of primary health
care systems since the earliest days and is still widely used
[1]. S. frutescens contains several essential, bioactive com-
pounds with clinically proven pharmacological activities
[2–4]. This makes the plant attractive as a medicine for
various ailments and diseases. Sutherlandia is recom-
mended by the South African Department of Health as a
supporting treatment for people living with Acquired
Immune Deficiency Syndrome (AIDS) as immune system
booster [5, 6]. It is also prescribed for treatment of cancer,
tuberculosis (TB), diabetes, anxiety and clinical depression
[6–8]. TB is a highly infectious disease caused by Myco-
bacterium tuberculosis and it kills millions of people annu-
ally. It is also one of the common co-infections in people
living with HIV/AIDs thus worsening the HIV/AIDS
pandemic.
New drugs with novel mechanisms of action are needed
to avoid the cross-resistance problem and more impor-
tantly to kill persister TB populations [9]. Advances in
molecular tools make it possible for identification of
targets essential for survival and persistence whose inhi-
bition is likely to shorten therapy. A study done by Zhang,
[10] reviewed various new drug targets and drug candi-
dates; among these was the enzyme shikimate kinase.
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Shikimate kinase is the fifth enzyme in the shikimate bio-
synthetic pathway from M. tuberculosis. This enzyme is
considered an excellent target for developing novel anti-
tuberculosis agents as the pathway in which it is involved
only takes place in microbes and some plants but is absent
in mammals [11]. The shikimate pathway involves seven
enzymatic steps in the biosynthesis of chorismate end
product, which in turn serves as the precursor for the syn-
thesis of the aromatic amino acids, folates, uniquinones,
mycobactins, menaquinones and napthoquinones [12].
The importance of this pathway has been proven in
culture using mutants whose growth is completely inhi-
bited without the provision of aromatic supplements [13].
This study was aimed at investigating the activity of S.
frutescens extracts against Mycobacterium tuberculosis
shikimate kinase enzyme (MtSK).
At the same time this research seeks to discover new
drugs from S. frutescens and hence contribute to the fight
against TB. There is little scientific data on the activity on
S. frutescens against TB. The only data available is mainly
from personal communications and laboratory reports, on
the use of S. frutescens plant extract for support treatment
in patients suffering from TB. The wide use of Sutherlandia
in traditional medicine and these preliminary findings
suggest that S. frutescens is a good candidate for discovery




About 1 kg of fresh aerial parts (the leaves and stems) of
Sutherlandia were collected at a community-based farm
in Petrusburg in the Free State, South Africa (29° 6.774′ S;
25° 24.305′ E; 1249 m above sea level). A twig containing
a flower was sent to the South African National Biodiver-
sity Institute (SANBI) for identification (SANBI voucher
specimen number: 428679). The plant material was finely
ground and stored at a room temperature until tests were
done.
Extraction procedure
Plant material extraction based on the traditional method
Dried ground aerial parts (leaves and stems) of S. frutescens
(50 g) were boiled in 2 L of distilled water using a hot plate
and a steel extraction vessel covered with an aluminium
foil, it was stirred occasionally. The suspension was then
removed from the hot plate, cooled in room temperature
and filtered through Whatman no.1 filter paper and
collected in a glass beaker. The aqueous extraction was
freeze-dried and a powder was subsequently obtained.
The extract was stored in an airtight container in the cold
room at 4 °C until further testing.
Plant material extractions using organic solvents
The dried and ground aerial parts of the plant (100 g)
were separated into 2 times 50 g each. One litre of 96 %
Ethanol was added to 50 g plant material stirred and left
overnight. The suspension was filtered the following day
using Whatman no.1 filter paper and evaporated to give
an ethanol extract (excess ethanol from the Whatman
no.1 extract was dried using a fume-hood overnight).
The remaining 50 g plant material was used to prepare
1:1 dichloromethane: methanol (DCM:MeOH; 1.4 L)
extract. The same procedure used to prepare the ethanol
extract was used to prepare the DCM:MeOH; 1:1 extract.
Shikimate kinase enzyme inhibition assay
A purified shikimate kinase enzyme was obtained from
Prof Kenyon at The Council for Scientific and Industrial
Research (CSIR) in South Africa and stored at −80 °C
was used for the assay and the stock solution was pre-
pared as per the Table 1.
The stock solution containing everything excluding the
inhibitor (extracts or fractions) and the ATP was prepared.
Extracts/fractions were weighed out to a concentration
of 10 mg/ml. Six Eppendorfs were prepared with 1:10
increasing dilution of the extract/fraction. To each Eppen-
dorfs 319 μl of stock solution was added plus the 25 μl of
the inhibitor at each concentration. To the blank 25 μl of
nH2O was added and 1.3 μl of 200 mM EDTA was also
added to this tube as a stopping reagent. To the rest of the
tubes having reaction mixtures and also to the blank
1.4 μl of 60 mM ATP was added, vortexed and incubated
for 15 min. HPLC vials were then lined up, labeled and
319 μl was distributed into each triplicates. The reaction
was started by the addition of 1 μM concentration of the
enzyme. The assay was done at 37 °C for 15 min. The
reaction was terminated by the addition of 2.5 μl 200 mM
EDTA. The samples were centrifuged for 2 min at
13,000 rpm and the ADP and ATP concentrations were
determined by HPLC. The shikimate kinase inhibition
assay is based on quantification of dissociated ADP from







K-PO4 buffer, pH 6.8 250 4760.0 100
MgCl2 60 39.7 0.2
ATP 60 39.7 0.2
Inhibitor 12 991.7 1
KCl 100 1190.0 10
Shikimic acid 100 238.0 2
Enzyme/dH20(nM) 100 1785.0 15
nH2O 2856.0
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the ATP molecule after its phosphate group has been
transferred to shikimate as shown on Fig. 1. The IC50
for the extracts or fractions were determined by plotting
and evaluating the data using Graph Pad prism software,
version 5.0. There are no positive controls of known
approved shikimate kinase inhibitors used to compare the
obtained results with because this study was the first using
this approach.
Fractionation of extracts using column chromatography
The solvent-solvent fractionation was selected to simplify
extracts by fractionating the chemical compounds into
broad groups based on their solubility. The fractions
collected were concentrated using the rotary evaporator
(Buchi Rotavapor) under reduced pressure, rotating at
100 rpm and with water bath at 40 °C. The fractions were
phytochemically analyzed using TLC. The separated com-
ponents were visualized with ultraviolet light (360 nm); the
plates were sprayed with vanillin-sulphuric acid reagent and
heated at 110 °C for colour development.
Fractionation of the plant extracts was done as follows:
DCM: MeOH 1:1 and ethanol extracts One gram of
each extract was dissolved in 100 % DCM, mixed with
silica gel and placed in a warm water bath until it has
dried up. A column was packed with 118 g silica gel and
100 % DCM was used to dissolve the silica gel and frac-
tions were eluted as follows:
Fraction 1 with 100 % DCM yields A
Fraction 2 with 30 % MeOH/DCM yields B
Fraction 3 with 70 % MeOH/DCM yields C
Fraction 4 with 100 % MeOH yields D
H2O extract One gram was dissolved in 100 % MeOH
and mixed with silica gel and placed in warm water bath
until it has dried up. A column was packed with 120 g
silica gel dissolved in 100 % MeOH and fractions were
eluted as follows:
Fraction 1 with 30 % DCM/acetone yields E
Fraction 2 with 100 % ethylacetate yields F
Fraction 3 and 4 with 100 % MeOH yields both G and H
All collected fractions were left to dry overnight under
the fume hood. The fractions with the compound(s) of
interest were pooled and preparative HPLC was run for
further fractionation and further bioassays.
Using preparative HPLC to separate the combined
fractions A&B
The DCM: MeOH fractions A and B produced in section
2.4 were combined to yield a mass of 2.381 g. A 100 mg of
these were dissolved in 5 ml methanol. Two HPLC pumps
shown on Tables 2 and 3 below were used. A total of 20
sub-fractions were collected and these 20 sub-fractions
were assayed against M. tuberculosis shikimate kinase
enzyme. The most active sub-fraction was found to be
sub-fraction 8.
Results and discussion
The shikimate enzyme is one of the most vital enzymes
involved in the metabolic pathways of Mycobacterium
tuberculosis. The principle of the shikimate kinase inhi-
bition assay is primarily based on the enzyme shikimate
Fig. 1 The fifth step of the shikimate pathway (http://en.wikipedia.org/wiki/Shikimate_kinase)
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kinase phosphorylating shikimic acid to form shikimate-
3-phosphate and a resultant ADP as shown in Fig. 1. In
the presence of a good inhibitor less or none of this
resultant ADP will be produced, an appropriate inhibitor
would bind where a phosphate is supposed to bind on
the shikimic acid and therefore subsequently restricting
its phosphorylation and hence producing no ADP. The
strongest inhibitor produces less ADP. After performing
a series of shikimate kinase inhibition assays on the
crude extracts it was noticed that the DCM: MeOH 1:1
extract was showing more potential in terms of inhib-
ition of the shikimate kinase enzyme’s activity and hence
had a fairly low average of ADP produced and also as
seen on Table 4 had an IC50 of 0.1 ug/ml (Fig. 2) which
was lower than the H2O (5.1 ug/ml) (Fig. 3) and the
ethanol (1.7 ug/ml) extracts (Fig. 4). This realization led to
the decision to performing more tests with this extract.
Percentage inhibition obtained from single point inhi-
bitions of the 20 sub-fractions produced via preparative
HPLC. Sample 1,13,14,18 and 20 shows almost 100 %
inhibition while sample 7 has almost 0 % inhibition
against shikimate kinase (Fig. 5). Of the 20 sub-fractions
that were collected, sub-fraction 8 was shown to be one
of the most active against the shikimate kinase enzyme
(Fig. 6), hence the decision to pursue its isolation and
characterization. Figure 6 shows that at just after 10 min, a













0.0 1.0 0 100 0 0
25.0 1.0 0 50 0 50
30.0 1.0 0 0 0 100
31.0 1.0 100 0 0 0
38.0 1.0 100 0 0 0
40.0 1.0 0 100 0 0
50.0 1.0 0 100 0 0





% HOH % MeOH % 0.1 % FA
HOH
% CAN
0.0 5.5 0 65 35 0
2.0 5.5 0 65 35 0
15.0 5.5 0 75 12 13
25.0 5.5 0 0 0 100
40.0 5.5 0 0 0 100
44.0 5.5 0 65 35 0
50.0 5.5 0 65 35 0
Column heater temperature: 60 °C
PDA: Scanning 210–600 nm
Collection: Hold time: 1 min, 2 min collection intervals for 20 vials
Table 4 IC50 values of all the extracts, fractions and sub fractions
Sample name IC50 value (μg/ml)
S. frutescens crude extracts (January)
H2O 5.1
EtOH 1.7
DCM: MeOH 1:1 0.1a





aThe extract or fraction was chosen for further analysis
Fig. 2 Effect of the DCM: MeOH 1:1 extract on the IC50
Fig. 3 Effect of the H2O extract on the IC50
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large peak of a compound (sub-fraction 8) with a molecular
ion peak at (m/z) 277.4 was collected and this compound
ionized in the negative electrospray ionization (ES-). This
compound had a bright yellow colour and was sticky upon
evaporation with the rotavap. The TLC plate on Fig. 7 also
showed a single band, meaning that separation did occur
and that a single compound was found in this sub-fraction
8. The most useful tool in identification of a compound in
chemistry is the SDBS assimilations software; this software
was very helpful in determining the structure and molecu-
lar formula of the isolated compound by using its proton
and carbon NMR spectra (Table 5). The protons and
the carbons of the isolated compound exactly matched
those assimilated with from the software hence the soft-
ware was able to identify the compound’s chemical for-
mula as C18H30O2 giving a total molecular mass of 278 u.
Its IUPAC name and structure were determined using
Chem Draw ultra 8 software and these are represented on
Fig. 8. The IUPAC name of the isolated compound was
found to be (9Z, 12Z, 15Z)-octadeca-9,12,15-trienoic acid
and its common name is alpha linolenic acid. IC50 of the
compound was also determined and recorded to be 3.7
ug/ml (Fig. 9). Alpha-linolenic (ALA) is an essential
omega-3 fatty acid that cannot be synthesized by the
human body and hence has to be supplied by dietary
sources such as fish, plants, walnuts, grape seed (canola),
several legumes, flaxseed, and green leafy vegetables and
vegetable oils [14, 15] but has not been reported to have
been isolated from S. frutescens before. Stark et al.
[14] mentioned that potential benefits of ALA include
cardio-protective effects, modulation of the inflammatory
response, and a positive impact on both central nervous
Fig. 5 Chart representing percentage inhibition of the single point inhibitions of the 20 sub-fractions produced via preparatory HPLC
Fig. 4 Effect of the EtOH extract on the IC50
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system function and behavior. According to Stark et al.
[14], as a result of many studies they have conducted in
their study, ALA is not only essential for dietary require-
ments but also has therapeutic properties. Several studies
have proven amongst other free fatty acids that alpha
linolenic acid is active against a wide range of microorga-
nisms including bacteria such as S. aureus and Bacillus
subtilis [16], Helicobacter pylori, [17] viruses such as
hepatitis C virus (HCV) [18] and fungi such as Rhizoctonia
solani and Crinipellis perniciosa [19]. According to Desbois
and Smith, [20] their antibacterial mode of action is not
clearly understood but may also result from the inhibition
of enzyme activity, impairment of nutrient uptake, gener-
ation of peroxidation and auto-oxidation degradation prod-
ucts or direct lysis of bacterial cells. The broad spectrum of
activity they possess, the non-specific mode of action and
their safety makes them attractive as antibacterial agents
for various applications in medicine, agriculture and food
preservation.
This is a novel study. Firstly, this is the first report on
identifying ALA from S. frutescens. Secondly, this is the
first report showing ALA from S. frutescens inhibiting
shikimate kinase enzyme, an important drug target for M.
tuberculosis. Thirdly, this is the first time that ADP quan-
tification method for shikimate kinase inhibition assay
using HPLC was used. In other words, a reliable HPLC
based M. tuberculosis shikimate kinase inhibition assay
was developed in this study. Several studies have used
Table 5 Spectroscopic data of the SDBS ALA assimilations and
the NMR from sub-fraction 8



















Fig. 6 Dose response curve determining the IC50 of sub-fraction 8
from the fractionation of fractions A&B of the June DCM: MeOH
1:1 extract
Fig. 7 TLC plates developed in different mobile phases. The TLC
plates were sprayed with 0.1 % vanillin-sulphuric acid. From left to
right, the first four lanes represent the H2O fractions, the next four
lanes represent EtOH fractions and the last four lanes represent
DCM:MeOH (1:1) fractions
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liquid chromatography-Mass spectrometry (LC-MS) to
determine M. tuberculosis shikimate kinase enzyme activity
by quantifying shikimate-3-phosphate which is a resulting
product of the phosphorylation of shikimate [21–23]. The
advantage of using the ADP method is that one can see
the viability of the enzyme by tracing the production of
ADP thus using the HPLC machine not only ensures the
collection of qualitative data but also the quantitative data.
The ADP method used in this study could be useful for
scientists to study other potential M. tuberculosis shi-
kimate kinase inhibitors. Kinases have a conserved phos-
phoryl transfer mechanism [24–26] thus to find a unique
inhibitor and a way of determining inhibition of kinases
advance kinases kinetic studies.
Conclusion
In conclusion, this study demonstrated that ALA from
S. frustescens is an inhibitor of shikimate kinase a good
drug target for Mycobacterium tuberculosis. Further
studies to test the isolated compound, ALA on whole M.
tuberculosis cells will be conducted.
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